Back to Search
Start Over
Oxindole-based intraocular pressure reducing agents
- Source :
- Bioorganic & Medicinal Chemistry Letters. 27:3787-3793
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- The study represents the new findings at the crossroads of chemistry and medicine, particularly between medicinal and organic chemistry and ophthalmology. In this work we describe how the chemical reactivity of indolinone scaffold may be used to create small molecule ligands with strong biological response comparable with and larger than that of endogenous hormone. The synthesis of oxindole-based melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) analogues was proposed and their ability to influence intraocular pressure (IOP) was studied in vivo. Time-dependent study revealed the prolonged effect (more than 6 h) of the lead-compound. This effect in combination with high IOP reducing effect (41 ± 6%) in low concentrations of the active compound (0.1 wt%) and with high water solubility represents a great potential of low-cost oxindole derivatives as potent antiglaucoma agents.
- Subjects :
- Models, Molecular
Intraocular pressure
Indoles
Time Factors
Reducing agent
Stereochemistry
Clinical Biochemistry
Pharmaceutical Science
Pharmacology
Crystallography, X-Ray
Ligands
010402 general chemistry
01 natural sciences
Biochemistry
Melatonin
Structure-Activity Relationship
chemistry.chemical_compound
In vivo
Drug Discovery
medicine
Humans
Oxindole
Enzyme Inhibitors
Quinone Reductases
Endogenous hormone
Molecular Biology
Intraocular Pressure
Dose-Response Relationship, Drug
Molecular Structure
010405 organic chemistry
Organic Chemistry
Small molecule
Oxindoles
0104 chemical sciences
chemistry
Active compound
Molecular Medicine
medicine.drug
Subjects
Details
- ISSN :
- 0960894X
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Bioorganic & Medicinal Chemistry Letters
- Accession number :
- edsair.doi.dedup.....f35e5c1b5c8081498ecd469d60334c14
- Full Text :
- https://doi.org/10.1016/j.bmcl.2017.06.065